| IN A NUTSHELL |
|
Across sub-Saharan Africa, malaria remains a significant threat to pregnant women and their unborn children. The disease often leads to severe complications such as miscarriage, stillbirth, low birth weight, and serious illness. In response to this pressing issue, a pioneering project funded by the European Union aims to develop a new malaria vaccine. This vaccine, designed to protect women before they become pregnant, could revolutionize maternal and newborn health in regions where malaria is endemic. As researchers work towards this goal, the hope is that safer pregnancies and healthier babies will become a reality for families across Africa.
A New Approach to Malaria Prevention
The ADVANCE-VAC4PM project is spearheading efforts to protect women from malaria before they even conceive. Coordinated by Dr. Flavia D’Alessio at the European Vaccine Initiative (EVI), the project seeks to develop a vaccine for adolescent girls who have never been pregnant. This approach is akin to the HPV vaccine, which provides long-lasting protection against cervical cancer. The aim is to shield women from the dangers of malaria as soon as they begin childbearing.
Dr. D’Alessio explains, “When a woman becomes pregnant for the first time, she is particularly vulnerable to malaria.” The malaria parasite can infect red blood cells, which then pass into the placenta, causing adverse outcomes for both mothers and their babies. By targeting young girls, the vaccine could potentially prevent these complications from occurring.
This innovative strategy could drastically reduce the number of malaria-related complications in pregnancies, offering new hope for maternal and newborn health.
Understanding the Human Impact
The statistics surrounding malaria’s impact on pregnancy are staggering. The World Health Organization (WHO) links malaria in pregnancy to between 75,000 and 200,000 infant deaths every year and more than 800,000 low-birthweight babies. Placental malaria, a condition caused by the malaria parasite binding to placental tissue, can also result in anemia and high blood pressure in expectant mothers.
The new vaccines in development aim to tackle this issue head-on. They target a malaria parasite protein called VAR2CSA, which is responsible for the parasite’s ability to bind to the placenta. While blocking this protein may not prevent infection altogether, it could protect pregnant women and their babies from the most severe consequences.
By focusing on the VAR2CSA protein, researchers hope to diminish the adverse effects associated with malaria during pregnancy, potentially saving thousands of lives each year.
Progress and Challenges in Vaccine Development
Two promising malaria vaccine candidates, PAMVAC and PRIMVAC, are currently in development. Created by the University of Copenhagen and the French National Institute of Health and Medical Research, respectively, both vaccines target similar regions of the VAR2CSA protein. Early trials have shown that these vaccines are safe, well-tolerated, and capable of producing a strong immune response.
The next critical step is to determine whether this immune response translates into real-world protection. Researchers plan to follow vaccinated women through pregnancy and childbirth to assess if they experience fewer cases of placental malaria compared to unvaccinated women. If successful, the vaccines will undergo further testing before obtaining national regulatory approval and WHO prequalification.
“We will need to follow women through this entire period to demonstrate protection,” says D’Alessio.
The journey to vaccine approval is long, but the potential benefits for maternal and child health are too significant to ignore.
International Collaboration and Field Trials
The ADVANCE-VAC4PM consortium unites 10 leading research institutions from Europe and Africa, all experienced in malaria vaccine development. This collaborative effort is coordinated by the EVI, a non-profit organization focused on accelerating the development of vaccines for diseases affecting low- and middle-income countries. The research builds on earlier work supported by international partnerships and funding bodies, underscoring the global nature of this initiative.
In Burkina Faso, field trials are being prepared by Professor Sodiomon Sirima and his team at the Groupe de Recherche Action en Santé. These trials involve vaccinating non-pregnant women and monitoring their immune responses over time. The goal is to confirm whether the vaccine’s protective effects persist once these women become pregnant.
Such international collaboration is vital for overcoming the challenges of malaria vaccine development and ensuring that effective prevention measures reach those who need them most.
Integrating New and Existing Malaria Prevention Strategies
If the new malaria vaccine receives approval, it will complement existing prevention strategies like insecticide-treated bed nets and intermittent preventive treatment in pregnancy (IPTp). Although IPTp has reduced perinatal mortality by about 27% in some cases, its effectiveness is limited by factors such as availability, resistance, and safety concerns during the first trimester.
“This is another reason why a malaria vaccine is so badly needed,” emphasizes D’Alessio. Beyond clinical research, the ADVANCE-VAC4PM team is investing in capacity building, training postgraduate students, mentoring early-career researchers, and developing digital tools to monitor pregnancy outcomes.
“If vaccinated women end up having fewer miscarriages, stillbirths, and low-weight babies, this will be a tremendous achievement for the vaccine and the malaria research community as a whole,” says Sirima.
The integration of new and existing strategies could significantly enhance efforts to combat malaria’s impact on pregnancy.
With two promising vaccine candidates advancing through trials and a robust international collaboration backing this effort, the fight against malaria during pregnancy is gaining momentum. The potential to save thousands of maternal and infant lives each year offers a beacon of hope. As research continues, the question remains: how can global health systems best support and implement these groundbreaking advancements to ensure a safer future for mothers and babies worldwide?
